Drugs / fosnetupitant
fosnetupitant
also known as
07-PNET · 08-PNET · Fosnetupitant chloride · FOSNETUPITANT CHLORIDE HYDROCHLORIDE · Fosnetupitant chloride hydrochloride component of akynzeo · Fosnetupitant chloride hydrochloride component of akynzeo for injection · Fosnetupitant dihydrochloride
Small molecule targets TACR1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | AKYNZEO | — | 2018-04-19 | fda.gov ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06840769 | Jun → Oct 2023 | — | Helsinn Healthcare SA | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06904235 | Jul 2025 → Oct 2027 expected | chemotherapy-induced toxicity | Helsinn Healthcare SA | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03403712 | Mar → Sep 2018 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-06-12 | Helsinn Healthcare SA | Results Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs helsinn.com ↗
Referring to the details of the publication below, these real-world data showed that healthcare resource utilization, such as CINV-related visits were significantly lower after AKYNZEO® compared to fosaprepitant/palonosetron (APPA). |
| 2023-02-03 | Helsinn Healthcare SA | Results Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs helsinn.com ↗
Results from the study indicate that CINV-related hospitalization costs were significantly lower in patients who received NEPA compared to aprepitant/fosaprepitant with ondansetron (APON) or aprepitant/fosaprepitant with palonosetron (APPA) (P <.0001 for both comparisons). |
| 2023-01-04 | Helsinn Healthcare SA | Results Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV in The Oncologist helsinn.com ↗
The analysis indicated that patients who experienced CR in their first cycle had a 93% or higher CR rates in subsequent cycles. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-24 | Helsinn Healthcare SA | Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US helsinn.com ↗ |
| 2023-06-12 | Helsinn Healthcare SA | Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs helsinn.com ↗ |
| 2023-02-03 | Helsinn Healthcare SA | Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs helsinn.com ↗ |
| 2023-01-04 | Helsinn Healthcare SA | Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV in The Oncologist helsinn.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fosnetupitant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03403712 ↗ |
| Known as | 07-PNET | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989917 ↗ |
| Known as | 08-PNET | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989917 ↗ |
| Known as | Fosnetupitant chloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989917 ↗ |
| Known as | FOSNETUPITANT CHLORIDE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989917 ↗ |
| Known as | Fosnetupitant chloride hydrochloride component of akynzeo | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989917 ↗ |
| Known as | Fosnetupitant chloride hydrochloride component of akynzeo for injection | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989917 ↗ |
| Known as | Fosnetupitant dihydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989917 ↗ |
| Action | Inhibit | “fosnetupitant, an antagonist of NK1 receptors” NCT06904235 ↗1“Neurokinin 1 receptor antagonist” CHEMBL3989917 ↗ |
| Modality | Small molecule | — CHEMBL3989917 ↗ |
| Route | Intravenous | “intravenous fosnetupitant/ palonosetron” NCT03403712 ↗ |
| Target | TACR1 | “Neurokinin 1 receptor antagonist” CHEMBL3989917 ↗ |